[go: up one dir, main page]

EE03688B1 - N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks - Google Patents

N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks

Info

Publication number
EE03688B1
EE03688B1 EE9800437A EE9800437A EE03688B1 EE 03688 B1 EE03688 B1 EE 03688B1 EE 9800437 A EE9800437 A EE 9800437A EE 9800437 A EE9800437 A EE 9800437A EE 03688 B1 EE03688 B1 EE 03688B1
Authority
EE
Estonia
Prior art keywords
preparation
heteroarylamines
heteroarylmethyl
phenyl
pharmaceutical composition
Prior art date
Application number
EE9800437A
Other languages
English (en)
Estonian (et)
Other versions
EE9800437A (et
Inventor
Gaston Venet Marc
Charles Sanz G�rard
Jean-Pierre Mabire Dominique
Fernand Armand Lacrampe Jean
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE9800437A publication Critical patent/EE9800437A/xx
Publication of EE03688B1 publication Critical patent/EE03688B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EE9800437A 1996-06-27 1997-06-19 N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks EE03688B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201781 1996-06-27
PCT/EP1997/003248 WO1997049704A1 (en) 1996-06-27 1997-06-19 N-[4-(heteroarylmethyl)phenyl]-heteroarylamines

Publications (2)

Publication Number Publication Date
EE9800437A EE9800437A (et) 1999-06-15
EE03688B1 true EE03688B1 (et) 2002-04-15

Family

ID=8224119

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800437A EE03688B1 (et) 1996-06-27 1997-06-19 N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks

Country Status (33)

Country Link
US (5) US6124330A (hu)
EP (1) EP0907650B1 (hu)
JP (1) JP3404749B2 (hu)
KR (1) KR100365312B1 (hu)
CN (1) CN1102593C (hu)
AR (1) AR007626A1 (hu)
AT (1) ATE229019T1 (hu)
AU (1) AU711575B2 (hu)
BG (1) BG63545B1 (hu)
BR (1) BR9710002A (hu)
CA (1) CA2258165C (hu)
CZ (1) CZ297769B6 (hu)
DE (1) DE69717627T2 (hu)
DK (1) DK0907650T3 (hu)
EE (1) EE03688B1 (hu)
ES (1) ES2188957T3 (hu)
HK (1) HK1018458A1 (hu)
HU (1) HU223093B1 (hu)
ID (1) ID17275A (hu)
IL (1) IL127740A (hu)
MY (1) MY116917A (hu)
NO (1) NO312102B1 (hu)
NZ (1) NZ333382A (hu)
PL (1) PL201704B1 (hu)
PT (1) PT907650E (hu)
RU (1) RU2190611C2 (hu)
SI (1) SI0907650T1 (hu)
SK (1) SK282769B6 (hu)
TR (1) TR199802709T2 (hu)
TW (1) TW490464B (hu)
UA (1) UA53649C2 (hu)
WO (1) WO1997049704A1 (hu)
ZA (1) ZA975698B (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0907650T3 (da) * 1996-06-27 2003-03-10 Janssen Pharmaceutica Nv N-4-(heteroarylmethyl)phenyl]-heteroaryl aminer
DK1037880T3 (da) 1997-12-11 2004-11-15 Janssen Pharmaceutica Nv Anilider som retinsyremimetika
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE19951701A1 (de) 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Imidazolyl-substituierten Carbinolen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
AU2003223672A1 (en) * 2002-04-17 2003-11-03 Tyco Healthcare Group Lp Method and apparatus for anastomosis including an expandable anchor
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2522430A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
WO2006036507A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
AU2005289998A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
AU2005290075A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
BRPI0516217A (pt) * 2004-09-28 2008-08-26 Allergan Inc compostos de 4-benzil-1,3-diidro-imidazol-2-tionas não-substituìdos e substituìdos que atuam como agonistas especìficos ou seletivos alfa2-adrenérgicos e métodos de utilização dos mesmos
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EP1981343B8 (en) * 2006-01-17 2015-06-24 Stiefel Laboratories, Inc. Treatment of inflammatory disorders with triazole compounds
US8188124B2 (en) 2006-10-17 2012-05-29 Stiefel Laboratories, Inc. Talarazole metabolites
CA2702307C (en) * 2007-10-18 2016-04-05 Dompe S.P.A. (r)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
GB0811091D0 (en) * 2008-06-17 2008-07-23 Cancer Rec Tech Ltd CYP26 Inhibitors
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
EP2576544A4 (en) 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
KR101108577B1 (ko) * 2010-07-28 2012-01-30 국제엘렉트릭코리아 주식회사 테이프 히터
RU2017135541A (ru) 2010-11-19 2019-02-08 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применения
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
CN106632051A (zh) * 2016-12-15 2017-05-10 青岛辰达生物科技有限公司 一种盐酸右美托咪定中间体的合成方法
CN106588780A (zh) * 2016-12-15 2017-04-26 青岛辰达生物科技有限公司 一种盐酸右美托咪定中间体的制备工艺
CN106588779A (zh) * 2016-12-15 2017-04-26 青岛辰达生物科技有限公司 一种合成盐酸右美托咪定中间体的方法
KR20210055340A (ko) 2019-11-07 2021-05-17 정화종 화물 커버
CN115462347B (zh) * 2021-08-13 2024-07-16 广州市妇女儿童医疗中心 视黄酸代谢通路在先天性巨结肠疾病中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
DE69132329T2 (de) 1990-04-25 2000-11-30 Nissan Chemical Industries, Ltd. Pyridazinonderivat
TW321649B (hu) 1994-11-12 1997-12-01 Zeneca Ltd
US5582832A (en) * 1995-06-06 1996-12-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Compositions for topical application to skin
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
DK0907650T3 (da) * 1996-06-27 2003-03-10 Janssen Pharmaceutica Nv N-4-(heteroarylmethyl)phenyl]-heteroaryl aminer

Also Published As

Publication number Publication date
BR9710002A (pt) 1999-08-10
CN1223654A (zh) 1999-07-21
HU223093B1 (hu) 2004-03-29
US20070088062A1 (en) 2007-04-19
PT907650E (pt) 2003-04-30
US6486187B1 (en) 2002-11-26
IL127740A0 (en) 1999-10-28
PL201704B1 (pl) 2009-04-30
CA2258165C (en) 2009-03-03
IL127740A (en) 2001-09-13
US20030176419A1 (en) 2003-09-18
US7205312B2 (en) 2007-04-17
RU2190611C2 (ru) 2002-10-10
HUP9902138A2 (hu) 1999-10-28
SK282769B6 (sk) 2002-12-03
NZ333382A (en) 2000-05-26
AU711575B2 (en) 1999-10-14
SI0907650T1 (en) 2003-06-30
KR20000016196A (ko) 2000-03-25
US20050113378A1 (en) 2005-05-26
JP2000503670A (ja) 2000-03-28
US6124330A (en) 2000-09-26
TR199802709T2 (xx) 1999-02-22
WO1997049704A1 (en) 1997-12-31
HK1018458A1 (en) 1999-12-24
BG103013A (en) 1999-09-30
NO312102B1 (no) 2002-03-18
PL330816A1 (en) 1999-06-07
AU3435697A (en) 1998-01-14
US6833375B2 (en) 2004-12-21
EE9800437A (et) 1999-06-15
CN1102593C (zh) 2003-03-05
ZA975698B (en) 1999-01-20
US7378433B2 (en) 2008-05-27
CZ297769B6 (cs) 2007-03-28
DE69717627T2 (de) 2003-09-18
NO986017L (no) 1999-02-19
UA53649C2 (uk) 2003-02-17
BG63545B1 (bg) 2002-04-30
HUP9902138A3 (en) 2001-10-29
KR100365312B1 (ko) 2003-03-06
AR007626A1 (es) 1999-11-10
DE69717627D1 (de) 2003-01-16
EP0907650A1 (en) 1999-04-14
SK178198A3 (en) 2000-05-16
TW490464B (en) 2002-06-11
NO986017D0 (no) 1998-12-21
ES2188957T3 (es) 2003-07-01
DK0907650T3 (da) 2003-03-10
ATE229019T1 (de) 2002-12-15
EP0907650B1 (en) 2002-12-04
CZ423198A3 (cs) 1999-05-12
JP3404749B2 (ja) 2003-05-12
ID17275A (id) 1997-12-18
MY116917A (en) 2004-04-30
CA2258165A1 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
EE9800437A (et) N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks
EE9800136A (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE9900147A (et) Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE9900018A (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
FR2779438B1 (fr) Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
CY2013003I1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
EE9600180A (et) Anti-HIV kompositsioon, meetod selle valmistamiseks ja selle kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231